197 Safety considerations in the treatment with anti-CGRP antibodies 9 RESULTS Over a span of three years, from mid-November 2018 to mid-November 2021, a comprehensive assessment was carried out to establish study eligibility, involving a total of 270 patients. The study’s inclusion process is visually presented in Figure 1. Among the patients considered for participation, a total of n=77 were excluded. Primary reasons for exclusion were previous treatment with anti-CGRP(R)-mAbs (n=43) or an increased CV risk due to hypertension at baseline (n=30), a history of hypertension (n=3) or a history of CV events (n=1). Figure 1. Flowchart of inclusion process
RkJQdWJsaXNoZXIy MjY0ODMw